Avadel Pharmaceuticals plc (AVDL)

Avadel Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	27.96	0	0	22.33	59.22
Revenue Growth (YoY)	-	-	-	-62.28%	-42.66%
Cost of Revenue	0.85	0	0	5.74	12.13
Gross Profit	27.12	0	0	16.59	47.09
Selling, General & Admin	151.71	74.52	68.5	32.41	30.18
Research & Development	13.26	20.7	17.1	20.44	32.92
Other Operating Expenses	0	3.35	-0.05	-45.4	7.26
Operating Expenses	164.97	98.56	85.55	7.45	70.36
Operating Income	-137.85	-98.56	-85.55	9.14	-23.27
Interest Expense / Income	9.89	12.34	9.94	12.99	12.48
Other Expense / Income	13.04	0.54	-2.34	1.23	2.83
Pretax Income	-160.78	-111.44	-93.15	-5.08	-38.58
Income Tax	-0.5	26.03	-15.82	-12.11	-5.36
Net Income	-160.28	-137.46	-77.33	7.03	-33.23
Shares Outstanding (Basic)	80	60	59	53	37
Shares Outstanding (Diluted)	80	60	59	55	37
Shares Change	33.41%	2.66%	6.54%	46.89%	0.21%
EPS (Basic)	-2.00	-2.29	-1.32	0.13	-0.89
EPS (Diluted)	-2.00	-2.29	-1.32	0.13	-0.89
Free Cash Flow	-128.51	-71.02	-77.34	-48.83	-38.2
Free Cash Flow Per Share	-1.60	-1.18	-1.32	-0.92	-1.02
Gross Margin	96.97%	-	-	74.29%	79.52%
Operating Margin	-492.97%	-	-	40.93%	-39.29%
Profit Margin	-573.17%	-	-	31.47%	-56.11%
Free Cash Flow Margin	-459.58%	-	-	-218.64%	-64.51%
EBITDA	-149.13	-97.6	-82.39	9.6	-23.61
EBITDA Margin	-533.29%	-	-	42.99%	-39.88%
Depreciation & Amortization	1.77	1.49	0.82	1.69	2.49
EBIT	-150.89	-99.1	-83.2	7.91	-26.1
EBIT Margin	-539.61%	-	-	35.43%	-44.07%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).